The US Food and Drug Administration (FDA) said it is unable to approve the Atara Biotherapeutics’ off-the-shelf" allogeneic T-cell immunotherapy Ebvallo (tabelecleucel) based on the company’s Biologics License Application (BLA). The regulator ruled that the single arm ALLELE trial, which Atara’s says was previously confirmed by the FDA as adequate to support the BLA filing, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!